Next Article in Journal
Differential Analysis of Gly211Val and Gly286Val Mutations Affecting Sarco(endo)plasmic Reticulum Ca2+-ATPase (SERCA1) in Congenital Pseudomyotonia Romagnola Cattle
Next Article in Special Issue
Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
Previous Article in Journal
Rat Group IIA Secreted Phospholipase A2 Binds to Cytochrome c Oxidase and Inhibits Its Activity: A Possible Episode in the Development of Alzheimer’s Disease
Previous Article in Special Issue
Oxidation of p-[125I]Iodobenzoic Acid and p-[211At]Astatobenzoic Acid Derivatives and Evaluation In Vivo
 
 
Article
Peer-Review Record

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy

Int. J. Mol. Sci. 2022, 23(20), 12369; https://doi.org/10.3390/ijms232012369
by Wendy Delbart 1,2,*, Jirair Karabet 3, Gwennaëlle Marin 3, Sébastien Penninckx 3, Jonathan Derrien 4,5, Ghanem E. Ghanem 1,2, Patrick Flamen 1 and Zéna Wimana 1,2
Reviewer 1:
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2022, 23(20), 12369; https://doi.org/10.3390/ijms232012369
Submission received: 22 August 2022 / Revised: 7 October 2022 / Accepted: 12 October 2022 / Published: 15 October 2022
(This article belongs to the Special Issue Targeted Radionuclide Therapy of Cancer and Infections)

Round 1

Reviewer 1 Report

Introduction is well written, and the author has the right emphasis on the lack of knowledge for the RNT radiobiology. However, I have a minor comment about the beginning of the introduction: It is better to say the “targeted RNT” is an effective systemic therapy. There are different RNT modalities that are not systemic such as 90Y-SIRT. 

 

Results:

Although the authors have provided number of analyses to benchmark the RNT and EBRT, I would like to have clarification on the method section. The comments and questions below are critical to understand whether the experiments were performed correctly. 

 

1.     Could the author provide the alpha and beta parameters for the 6 cell lines. These radiobiological parameters are critical for the design of the 177Lu treatment of the cells. Could the author also calculate the initial dose rate at which the cells were treated with 177 Lu (both with Cl3 and DOTATATE cases). The cell dosimetry was considered 10 days incubation of the 177Lu, however, I am not sure if the dose rate was dropped below the critical dose rate at sometime during the cell treatment. Any absorbed dose beyond the critical dose rate is wasted. So, it is important to choose an initial dose rate that does not drops beyond the critical dose rate during the incubation time. Otherwise, the cell dosimetry is not accurate. 

2.     In this study the 5 MBq of 177Lu (both with Cl3 and DOTATATE form) was compared against the 2 Gy acute dose of EBRT. However, the dose rate at which the dose is delivered to the cells are different (i.e., the EBRT is acute with G factor of ≈1 and 177Lu is exponentially decreasing with a G factor of much less than 1). For benchmarking, similar dose rate of different type of radiation is required. I think the author might need to include an additional set of experiment including the fractionated EBRT cell treatment. 

3.     I think it make more sense to include the BED calculation to this work since this study is focusing on the understanding the radiobiological mechanisms induced by RNT and EBRT. 

4.     For MC simulation, are the cells overlapping? What algorithm has the author used to create the cell cluster?

5.     For MC simulation, the branching ratios are incorrect (e.g., the beta- particle branching ratio should be ≈ 79%), please check the IAEA nuclear data (see the link below). The simulation work needs to be repeated by the correct branching ratio.

https://www-nds.iaea.org/relnsd/vcharthtml/VChartHTML.html

 

Also for figure 1 (b), 3, 4,6, there are some word overlapped with the y-axis title. 

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

see attached file

Comments for author File: Comments.docx

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

None.

Back to TopTop